NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20 | -85.1% | 34,167 | -85.4% | 0.00% | -100.0% |
| Q2 2023 | $134 | -49.6% | 234,257 | -38.2% | 0.00% | -66.7% |
| Q1 2023 | $266 | -72.0% | 379,117 | -9.8% | 0.00% | -76.9% |
| Q4 2022 | $950 | -99.9% | 420,455 | +80.6% | 0.01% | +62.5% |
| Q3 2022 | $744,000 | +72.6% | 232,805 | +105.2% | 0.01% | +60.0% |
| Q2 2022 | $431,000 | -76.5% | 113,460 | -66.6% | 0.01% | -61.5% |
| Q1 2022 | $1,832,000 | +224.2% | 339,914 | +980.1% | 0.01% | +333.3% |
| Q3 2021 | $565,000 | +7.4% | 31,472 | +2.5% | 0.00% | -40.0% |
| Q2 2021 | $526,000 | +11.0% | 30,692 | +29.3% | 0.01% | 0.0% |
| Q1 2021 | $474,000 | +74.3% | 23,741 | +44.6% | 0.01% | -37.5% |
| Q3 2020 | $272,000 | -33.8% | 16,421 | -7.6% | 0.01% | -33.3% |
| Q2 2020 | $411,000 | +67.1% | 17,770 | +55.8% | 0.01% | +9.1% |
| Q4 2019 | $246,000 | -4.3% | 11,404 | -19.3% | 0.01% | -8.3% |
| Q3 2019 | $257,000 | -39.0% | 14,124 | +63.8% | 0.01% | -92.2% |
| Q2 2018 | $421,000 | – | 8,625 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |